School of Medical & Allied Sciences Faculty

Dr. Vikas Jhawat

Associate Professor, Pharmaceutics

Qualification: Master degree and bachelor degree, PhD

College/University: Maharishi Markandeshwar (Deemed to be) University

Introduction: Dr. Vikas Jhawatis an expert in the area of dosage formulation development using the novel techniques. He is teaching Quality Assurance, Cosmetic Science and Industrial Pharmacy at GD Goenka University (India).

Prior to joining GD Goenka University in 2018; he worked as an Assistant Professor in Maharishi Markandeshwar (Deemed to be) University (India). Vikas also worked as a Quality Control Analyst in Venus Remedies, Baddi; Himachal Pradesh and was engaged in the testing of anticancer, antibiotics and analgesic drugs. He has hands-on experience on sophisticated instruments such as HPLC, GC, UV spectroscopy, FTIR and other analytical instruments.

Vikas Jhawat holds PhD degree; Master degree and bachelor degree from Maharishi Markandeshwar (Deemed to be) University (India).

He has also done PG diplomas in Pharma Regulatory Affairs form BII, Noida and Product Management from ISBM, Chandigarh.

Publications (from 2015)

Scholarly Journals

‘Formulation and Evaluation of Thermosensitive Flurbiprofen In Situ Nano Gel for the Ocular Delivery’, Journal of Biomaterials Science, Polymer Edition, (Maddiboyina, B., Jhawat, V., Desu, P.K., Gandhi, S., Nakkala, R.K., and Singh, S., 2021)

‘3D Printing Technology in Pharmaceutical Dosage forms: Advantages and Challenges’, Current Drug Targets, (Desu, P.K., Rao, G.S.N.K., Maddiboyina, B., Vanitha, K., Anusha, R., Jhawat, V., 2021).

‘Application of 32 Factorial Designs for Optimization and Characterization of Mucoadhesive Microspheres of Aceclofenac’, Int. J. Res. Pharm. Sci., 12(2), pp.-1-10, (Maddiboyina, B., Desu, P.K., Rao, G.S.N.K., Bandaru, N., Soujanya, C.S., Satya, B.L., Anusha, R., Jhawat, V., 2021).

‘Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension’, Heliyon, 6(11):e05459, (Maddiboyina, B., Hanumanaik, M., Nakkala, R.K., Jhawat, V., Rawat, P., Alam, A., Foudah, A.I., Alrobaian, M.M., Shukla, R., Singh, S., Kesharwani, P., 2020).

‘Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy’, Journal of Controlled Release, 327, pp. 500-511, (Jhawat, V., Gulia, M., Gupta, S., Maddiboyina, B., and Dutt, R., 2020).

‘Fate and Applications of Superporous Hydrogel Systems: A Review’, Current Nanomedicine, 10, pp. 1-16, (Jhawat, V., Gulia, M., Maddiboyina, B., Dutt, R. and Gupta, S., 2020).

‘Lipoidal Nano Architect for Parental Drug Delivery: Formulation Development and Regulatory Concerns’, Current Applied Polymer Science, 4, pp. 1-9, (Jhawat, V., Sharma, A.K., Garg, V., Dutt, R., Gulia, M., 2020).

‘Unwinding Complexities of Diabetic Alzheimer by Potent Novel Molecules’, American Journal of Alzheimer’s Disease & Other Dementias’, 35, pp. 1-17, (Gupta, S., Nair, A., Jhawat, V., Mustaq, N., Sharma, A., Dhanawat, M., & Khan, S.A., 2020).

‘A Review on Expedient Assets of Polymers Employed in Novel Topical Formulation for Successful Treatment of Arthritis’, Current applied polymer science, 4, 1, (Nishal, S., Jhawat, V., Phaugat, P., 2020).

‘A Review on Nanoparticle Based Herbal Remedies for the Management of Alopecia’, Der Pharmacia Lettre, 12 (5), 1-17, (Maddiboyina, B., Jhawat, V., Ramesh, K., Nakkala, R.K., Jakka, A.L., 2020).

‘Formulation development and characterization of controlled release core in cup matrix tablets of venlafaxine HCl’, Current Drug Therapy, 15, 1, (Maddiboyina, B., Jhawat, V., Sivaraman, G., Sunnapu, O.P., Nakkala, R.K., Naik, M.H., Gulia, M., 2020).

‘Alpha adducin (ADD1) gene polymorphism and new onset of diabetes under the influence of selective antihypertensive therapy in essential hypertension’, Current Hypertension Reviews, 15(2), pp. 123-134. (Gupta, S., Jhawat, V., Agarwal, B.K., Roy, P., Saini, V., 2019).

‘Angiotensin converting enzyme gene insertion/deletion polymorphism is not responsible for antihypertensive therapy induced new onset of type 2 diabetes in essential hypertension’, Clinical Medicine Insights: Endocrinology and Diabetes, 12, pp. 1–10. (Jhawat, V., Gupta, S., Agarwal, B.K., Roy, P., Saini, V., 2019).

‘Prevalence and risk factors of essential hypertension and new onset of diabetes in essential hypertension in rural population of Haryana’, International Journal of Pharmacy and Pharmaceutical Sciences, 10 (2),pp. 142-148. (Jhawat, V., Gupta, S., Agarwal, B.K., Roy, P. and Saini, V., 2018).

‘Anti-inflammatory and anti-arthritic activity of different milk-based formulation of curcumin in rat model’, Current Drug Delivery, 15 (2), pp. 205-214. (Gupta, S., Kumria, R., Chauhan, S., Chattopadhyaya, I., Jhawat, V. and Sharma, M., 2018).

‘Comparison of the prescription pattern of antihypertensive drug therapy over time and its association with severity of essential hypertension’, International Journal of Pharma Research and Health sciences, 5, pp. 1994-1998. (Jhawat, V., Gupta, S., Agarwal, B.K., Roy, P. and Saini, V., 2017).

‘Quality by design (QbD) approach of pharmacogenomics in drug designing and formulation development for optimization of drug delivery systems’, Journal of Controlled Release, 245, pp. 15-26. (Gupta, S., Jhawat, V., 2017).

‘Induction of type 2 diabetes mellitus with antihypertensive therapy: is there any role of alpha adducin, ACE, and IRS-1 gene? Value in health regional issues, 12,pp. 90 – 98. (Gupta, S., Jhawat, V., 2017).

‘Formulation and evaluation of novel controlled release of topical pluronic lecithin organogel of mefenamic acid’,Drug delivery,23(9), pp. 3573-3581. (Jhawat, V., Gupta, S. and Saini, V., 2016).

Book Chapter

‘Pathophysiology of alzheimer disease: current drug therapy’, in Rahman, A., (Ed.),Frontier in clinical drug research-Alzheimer disorders, 6. (Gupta, S. and Jhawat, V., 2017) pp. 87-109.

Research

Vikas Jhawat’s current research interests are focused on formulation development of novel dosage forms for cancer, diabetes, hypertension and other diseases based on the genetic biomarkers derived from pharmacogenomics and nanotheranostic principle.